ROIV
Roivant Sciences LtdNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$20.16B
P/E Ratio
—
EPS
$-1.17
Beta
1.21
52W High
$30.33
52W Low
$9.57
50-Day MA
$26.71
200-Day MA
$18.99
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Roivant Sciences Ltd
Roivant Sciences Ltd (ROIV) is a pioneering biopharmaceutical company focused on transforming the way therapies are developed and commercialized, utilizing a distinctive model that leverages proprietary technologies. With a diverse pipeline addressing critical unmet needs in neurology, immunology, and rare diseases, Roivant aims to streamline the drug development process, thereby reducing time and costs associated with bringing new therapies to market. The company's strong leadership team and strategic partnerships further enhance its potential to disrupt the healthcare landscape, creating significant value for investors while improving patient outcomes.
Fundamentals
| Revenue (TTM) | $13.31M |
| Gross Profit (TTM) | $-614.67M |
| EBITDA | $-1.26B |
| Operating Margin | -16965.00% |
| Return on Equity | -19.10% |
| Return on Assets | -14.50% |
| Revenue/Share (TTM) | $0.02 |
| Book Value | $6.02 |
| Price-to-Book | 4.75 |
| Price-to-Sales (TTM) | 1514.75 |
| EV/Revenue | 1191.73 |
| EV/EBITDA | 0.74 |
| Quarterly Earnings Growth (YoY) | -96.10% |
| Quarterly Revenue Growth (YoY) | -77.80% |
| Shares Outstanding | $715.70M |
| Float | $532.18M |
| % Insiders | 22.77% |
| % Institutions | 72.88% |
Analyst Ratings
Consensus ($33.75 target)
2
Strong Buy10
Buy1
HoldData last updated: 4/9/2026